<DOC>
	<DOCNO>NCT01067274</DOCNO>
	<brief_summary>A Randomized Multicenter Phase III Study Evaluate Role All-trans Retinoic Acid ( ATRA ) Combination Induction Chemotherapy , Azacitidine Idarubicin salvage therapy Idarubicin Cytarabine Azacitidine Maintenance Therapy Older Patients Acute Myeloblastic Leukemia ( AML ) . To compare outcome elderly patient newly-diagnosed AML treat standard induction chemotherapy post-remission therapy , patient CR , either azacitidine cytarabine combine idarubicin +/- ATRA salvage therapy azacitidine combine idarubicin +/- ATRA .</brief_summary>
	<brief_title>ALFA-0703 Study Older Patients With Acute Myeloblastic Leukemia ( AML )</brief_title>
	<detailed_description>Induction therapy : First randomization ( R1 ) baseline : ATRA versus ATRA . Salvage therapy : No conventional salvage therapy plan . Patients achieve CR , accord IWG criterion induction treat 3 course azacitidine idarubicin +/- ATRA combination , eligible treatment . Followed 3 identical course 6 course maintenance azacitidine alone deliver every 28 day , patient reach CR PR 3 course ( evaluation response 28 56 day course 3 ) . Randomization R2 : type maintenance : Response induction evaluate 2 week myeloid recovery , first consolidation course , due use pegfilgrastim , lenograstim filgrastim induction . Responses classify accord Revised Recommendations IWG AML . Patients CR subject second randomization R2 follow 6 course combine chemotherapy , deliver outpatient , ATRA accord R1 randomization .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>1 . Aged 65 79 year 2 . With morphologically prove diagnosis AML accord WHO classification either de novo AML `` myelodysplasia related change '' 3 . Not previously treat AML 4 . Signed informed consent . 1 . APL WHO classification . 2 . Ph1positive AML prior Ph1positive disease 3 . AML evolve prior MPN WHO 2008 classification . 4 . Prior treatment chemotherapy radiotherapy another tumor 5 . Prior tumor , stable least two year , except insitu carcinoma skin carcinoma 6 . Prior advance malignant hepatic tumor 7 . ECOG Performance Status Score &gt; 2 8 . Creatinine level 2x 's upper limit normal range ( ULN ) laboratory analysis perform , except AMLrelated . 9 . Total serum bilirubin 2x 's ULN laboratory analysis perform , except AMLrelated . 10 . AST ( SGOT ) ALT ( SGPT ) 2.5x 's ULN laboratory analysis perform , except AMLrelated 11 . LVEF le than.55 equivalent doppler echocardiography 12 . Known intolerance Azacitidine , mannitol , retinoids 13 . Positive serum test HIV HTLV1 14 . NYHA Grade 3/4 cardiac disease . 15 . Severe infection inclusion time . 16 . Psychiatric disease history noncompliance medical regimens patient consider potentially unreliable . 17 . Absence health care insurance ( affiliation à un régime de Sécurité Sociale ) 18 . Participation study require inform consent</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Aged 65 79 year</keyword>
	<keyword>Older Patients Acute Myeloblastic Leukemia</keyword>
</DOC>